Page 157 - 2019年1月第30卷第2期

requirement for PARP-1 for the assembly or stability of [55] YAN PW，HUANG XE，YAN F，et al. Influence of MDR1
XRCC1 nuclear foci at sites of oxidative DNA damage[J]. gene codon 3435 polymorphisms on outcome of plati-
Nucleic Acids Res，2003，31（19）：5526-5533. num-based chemotherapy for advanced non small cell
[41] 康世荣.XRCC1基因多态性和环境因素与非小细胞肺癌 lung cancer[J]. Asian Pac J Cancer Prev，2011，12（9）：
易感性的相关性研究[D].广州：南方医科大学，2016. 2291-2294.
[42] ZHAO W，HU L，XU J，et al. Polymorphisms in the base [56] YIN JY，HUANG Q，ZHAO YC，et al. Meta-analysis on
excision repair pathway modulate prognosis of plati- pharmacogenetics of platinum-based chemotherapy in non
num-based chemotherapy in advanced non-small cell lung small cell lung cancer（NSCLC）patients[J]. PLoS One，
cancer[J]. Cancer Chemother Pharmacol，2013，71（5）： 2012，7（6）：e38150.
1287-1295. [57] WEI HB，HU J，SHANG LH，et al. A meta-analytic re-
[43] ZHANG L，MA W，LI Y，et al. Pharmacogenetics of DNA view of ERCC1/MDR1 polymorphism and chemosensitiv-
repair gene polymorphisms in non-small-cell lung carcino- ity to platinum in patients with advanced non-small cell
ma patients on platinum-based chemotherapy[J]. Genet lung cancer[J]. Chin Med J：Engl，2012，125（16）：2902-
Mol Res，2014，13（1）：228-236. 2907.
[44] JEGGO PA，LÖBRICH M. How cancer cells hijack DNA [58] PAN JH，HAN JX，WU JM，et al. MDR1 single nucleotide
double-strand break repair pathways to gain genomic in- polymorphism G2677T/A and haplotype are correlated
stability[J]. Biochem J，2015，471（1）：1-11. with response to docetaxel-cisplatin chemotherapy in pa-
[45] XIONG Y，HUANG BY，YIN JY. Pharmacogenomics of tients with non-small-cell lung cancer[J]. Respiration，
platinum-based chemotherapy in non-small cell lung can- 2009，78（1）：49-55.
cer：focusing on DNA repair systems[J]. Med Oncol， [59] 黄燕，沈燕，郭皓，等.肺癌患者 GSTP1 基因启动子甲基
2017. DOI：10.1007/s12032-017-0905-6. 化检测及其临床价值[J].中华肿瘤防治杂志，2017，24
[46] 罗文婷.X-线修复交叉互补基因多态性及环境因素与非 （4）：242-246.
小细胞肺癌的流行病学研究[D].福州：福建医科大学， [60] 吕红英，李启才，卫红军，等.GSTP1、XPG基因多态性与
2012. 晚期非小细胞肺癌患者铂类药物化疗疗效及生存期的
[47] LIAO WY，SHIH JY，CHANG GC，et al. Genetic poly- 关系[J].中国癌症杂志，2012，22（8）：609-617.
morphism of XRCC1 Arg399Gln is associated with sur- [61] SUN N，SUN X，CHEN B，et al. MRP2 and GSTP1 poly-
vival in non-small-cell lung cancer patients treated with morphisms and chemotherapy response in advanced
gemcitabine/platinum[J]. J Thorac Oncol，2012，7（6）： non-small cell lung cancer[J]. Cancer Chemother Pharma-
973-981. col，2010，65（3）：437-446.
[48] QIU M，XU L，YANG X，et al. XRCC3 Thr241Met is as- [62] ZHOU F，YU Z，JIANG T，et al. Genetic polymorphisms
sociated with response to platinum-based chemotherapy of GSTP1 and XRCC1：prediction of clinical outcome of
but not survival in advanced non-small cell lung cancer platinum-based chemotherapy in advanced non-small cell
[J]. PLoS One，2013，8（10）：e77005. lung cancer（NSCLC）patients[J]. Swiss Med Wkly，2011.
[49] YIN JY，HUANG Q，YANG Y，et al. Characterization and DOI：10.4414/smw.2011.13275.
analyses of multidrug resistance-associated protein 1 [63] LV H，HAN T，SHI X，et al. Genetic polymorphism of
（MRP1/ABCC1） polymorphisms in Chinese population GSTP1 and ERCC1 correlated with response to plati-
[J]. Pharmacogenet Genomics，2009，19（3）：206-216. num-based chemotherapy in non-small cell lung cancer
[50] SZAKÁCS G，PATERSON JK，LUDWIG JA，et al. Target- [J]. Med Oncol，2014. DOI：10.1007/s12032-014-0086-5.
ing multidrug resistance in cancer[J]. Nat Rev Drug Dis- [64] YANG Y，XIAN L. The association between the GSTP1
cov，2006，5（3）：219-234. A313G and GSTM1 null/present polymorphisms and the
[51] 高歌.ABCC2、ABCB1 和 ABCG2 基因多态性与肺癌铂 treatment response of the platinum-based chemotherapy in
类化疗的相关性分析[D].上海：复旦大学，2010. non-small cell lung cancer （NSCLC） patients：a me-
[52] 刘肖腾.MDR1 基因多态性与膀胱癌发病风险相关性研 ta-analysis[J]. Tumour Biol，2014，35（7）：6791-6799.
究[D].天津：天津医科大学，2016. [65] 包晓玲，杨磊.中国人群GSTM1基因多态性与非吸烟肺
[53] CHEN S，HUO X，LIN Y，et al. Association of MDR1 and 癌发病风险的Meta分析[J].军医进修学院学报，2012，33
ERCC1 polymorphisms with response and toxicity to cis- （8）：849-852、892.
platin-based chemotherapy in non-small-cell lung cancer [66] LI W，YUE W，ZHANG L，et al. Polymorphisms in
patients[J]. Int J Hyg Environ Health，2010，213（2）： GSTM1，CYP1A1，CYP2E1，and CYP2D6 are associated
140-145. with susceptibility and chemotherapy response in non-
[54] VIÑOLAS N，PROVENCIO M，REGUART N，et al. Sin- small-cell lung cancer patients[J]. Lung，2012，190（1）：
gle nucleotide polymorphisms in MDR1 gen correlates 91-98.
with outcome in advanced non-small-cell lung cancer pa- （收稿日期：2018-03-12 修回日期：2018-09-06）
tients treated with cisplatin plus vinorelbine[J]. Lung Can- （编辑：张元媛）
cer，2011，71（2）：191-198.

·288 · China Pharmacy 2019 Vol. 30 No. 2 中国药房 2019年第30卷第2期